This lecture will review some of the new drugs recently FDA approved for management of lymphoma such as CAR-T therapy for relapsed/refractory Mantle Cell Lymphoma or follicul
|
Lyn Filip, RN, BSN, OCN will provide an introduction into the benefits of Pet Therapy in a clinical oncology setting.
|
In this course, Mary Dunn, MSN, RN, NP-C, OCN, will go into more detail for treatment options and considerations for treating localized prostate cancer and the management of side effects.
|
In this course, Mary Dunn, MSN, RN, NP-C, OCN, will provide a general overview of Prostate Cancer. The audience will learn about basic pathophysiology and epidemiology as it relates to both local and advanced disease. This course will then provide insight into the pros & cons of prostate cancer screening as well as the accepted diagnostic procedures & scoring.
|
In this course, Mary Dunn, MSN, RN, NP-C, OCN, will discuss the different treatment options for advanced prostate cancer as well as considerations for management side effects and maximizing a survivor’s quality of life.
|
Megan McElfresh, PA-C, provides an overview of the pathophysiology, diagnosis, prevention, and treatment of graft vs host disease post hematopoietic stem cell transplant.
|
Cindy Kelly, FNP-BC, ACHPN, and Vineeta Rao, PharmD, BCPS, review opioid and nonopioid treatment options for cancer-related pain. Their presentation addresses patients with cancer and substance use disorder and also cancer patients that are in remission, but who still present with persistent pain.
|
Siddharth Sheth, DO, MPH, will provide a brief overview of clinical factors relevant to head and neck cancers and basic management. Themain focus will be the current use of technologies that aid with the diagnosis, treatment selection, and monitoring of patientswith head and neck cancers. This includes next generation sequencing assays for DNA sequencing, RNA sequencing, andcirculating tumor DNA. The goal of the presentation is for providers to be comfortable with ordering and basic interpretation ofthese tests.
|
Brian Colwell Jensen, MD, will introduce the audience to potential cardiovascular adverse effects of contemporary cancer therapeutics.
|
Joshua F. Zeidner, MD, will discuss the evolving diagnostic algorithm for AML-MRC, prognosis, treatment outcomes, and unmet needs.
|